LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre Sells 68,906 Shares

LeMaitre Vascular, Inc. (NASDAQ:LMAT) CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction dated Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the completion of the transaction, the chief executive officer now directly owns 2,133,428 shares in the company, valued at $161,500,499.60. The sale was disclosed in a document filed with the SEC, which is available at this link.

LeMaitre Vascular Stock Performance

Shares of NASDAQ LMAT traded down $0.90 during mid-day trading on Wednesday, reaching $75.00. 109,442 shares of the company’s stock were exchanged, compared to its average volume of 122,731. The firm has a market capitalization of $1.68 billion, a price-to-earnings ratio of 50.26, a PEG ratio of 2.99 and a beta of 0.88. LeMaitre Vascular, Inc. has a 52-week low of $44.27 and a 52-week high of $76.24. The company’s 50-day moving average is $66.47 and its 200-day moving average is $59.23.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, beating analysts’ consensus estimates of $0.39 by $0.05. LeMaitre Vascular had a net margin of 16.99% and a return on equity of 11.57%. The business had revenue of $53.48 million during the quarter, compared to analysts’ expectations of $51.50 million. During the same period last year, the business earned $0.27 earnings per share. The business’s revenue for the quarter was up 13.6% on a year-over-year basis. As a group, equities analysts predict that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th will be paid a dividend of $0.16 per share. This represents a $0.64 dividend on an annualized basis and a yield of 0.85%. The ex-dividend date of this dividend is Wednesday, May 15th. LeMaitre Vascular’s dividend payout ratio (DPR) is 42.38%.

Institutional Investors Weigh In On LeMaitre Vascular

Institutional investors have recently modified their holdings of the company. Mesirow Institutional Investment Management Inc. purchased a new stake in LeMaitre Vascular during the fourth quarter worth about $8,837,000. Congress Asset Management Co. MA increased its position in shares of LeMaitre Vascular by 36.3% in the 3rd quarter. Congress Asset Management Co. MA now owns 508,379 shares of the medical instruments supplier’s stock valued at $27,696,000 after purchasing an additional 135,266 shares during the last quarter. Ranger Investment Management L.P. raised its holdings in LeMaitre Vascular by 15.8% during the third quarter. Ranger Investment Management L.P. now owns 898,822 shares of the medical instruments supplier’s stock worth $48,968,000 after purchasing an additional 122,601 shares in the last quarter. Summit Creek Advisors LLC increased its position in LeMaitre Vascular by 37.8% during the fourth quarter. Summit Creek Advisors LLC now owns 228,501 shares of the medical instruments supplier’s stock worth $12,970,000 after buying an additional 62,737 shares during the period. Finally, Conestoga Capital Advisors LLC raised its stake in LeMaitre Vascular by 3.0% during the 3rd quarter. Conestoga Capital Advisors LLC now owns 1,917,581 shares of the medical instruments supplier’s stock valued at $104,470,000 after acquiring an additional 55,895 shares during the last quarter. 84.64% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Stifel Nicolaus upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and raised their price objective for the company from $59.00 to $75.00 in a report on Friday, April 26th. JMP Securities increased their price objective on shares of LeMaitre Vascular from $72.00 to $77.00 and gave the company a “market outperform” rating in a report on Friday, May 3rd. StockNews.com upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating in a report on Friday, May 3rd. KeyCorp assumed coverage on LeMaitre Vascular in a research report on Tuesday, February 6th. They set a “sector weight” rating on the stock. Finally, Barrington Research raised their target price on LeMaitre Vascular from $69.00 to $79.00 and gave the stock an “outperform” rating in a research note on Friday, May 3rd. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $73.83.

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.